Naurex Lands $38,000,000 Series B Financing
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=22c6625e-55ff-47d3-9b6f-3c65b01211b6&Preview=1 - Date
12/17/2012 - Company Name
Naurex - Mailing Address
1801 Maple Ave. Evanston, IL 60201 - Company Description
Naurex Inc. is a clinical-stage company developing novel therapies for depression and other CNS disorders based on a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR). - Website
http://www.naurex.com - Transaction Type
Venture Equity - Transaction Amount
$38,000,000 - Transaction Round
Series B - Proceeds Purposes
Naurex will use the proceeds from the Series B financing to fund a number of key programs from its NMDA receptor modulator platform, including conducting a Phase Ilb trial of GLYX-13, the company’s lead NMDA receptor modulator in development for the treatment of depression, advancing its second-generation compound NRX-1074 into Phase I and Il clinical trials in depression and further developing its second- and third-generation programs for other CNS disorders. - M&A Terms
- Venture Investor
Baxter Ventures - Venture Investor
Adams Street Partners - Venture Investor
Latterell Venture Partners - Venture Investor
Genesys Capital - Venture Investor
Lundbeckfond Ventures - Venture Investor
Takeda Ventures - Venture Investor
Shire Pharmaceuticals
